BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32601266)

  • 21. Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas.
    Park JC; Ma TM; Rooper L; Hembrough T; Foss RD; Schmitt NC; Sawhney R; Flanders A; Kang H
    Head Neck; 2018 Dec; 40(12):E100-E106. PubMed ID: 30478962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-Line Treatment of Widely Metastatic
    Lin VTG; Nabell LM; Spencer SA; Carroll WR; Harada S; Yang ES
    J Natl Compr Canc Netw; 2018 Oct; 16(10):1166-1170. PubMed ID: 30323086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands.
    Boon E; van Boxtel W; Buter J; Baatenburg de Jong RJ; van Es RJJ; Bel M; Fiets E; Oosting SF; Slingerland M; Hoeben A; Tesselaar MET; Jonker MA; Flucke UE; ; van der Graaf WTA; van Herpen CML
    Head Neck; 2018 Mar; 40(3):605-613. PubMed ID: 29272069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance.
    Xu B; Dogan S; Haroon Al Rasheed MR; Ghossein R; Katabi N
    Hum Pathol; 2019 Nov; 93():30-36. PubMed ID: 31430492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma: a case report.
    Njiaju UO; Truica CI
    Clin Breast Cancer; 2010 Feb; 10(1):E3-5. PubMed ID: 20133250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
    Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
    Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A case of metastatic salivary duct carcinoma successfully treated with trastuzumab-based targeted therapy].
    Iguchi F; Taniguchi Z; Kusano J; Takahashi Y; Murai N
    Nihon Jibiinkoka Gakkai Kaiho; 2014 Aug; 117(8):1108-14. PubMed ID: 25255650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HER2/HER3-positive metastatic salivary duct carcinoma in the pleural effusion: A case report.
    Murata K; Kawahara A; Ono T; Takase Y; Abe H; Naito Y; Akiba J
    Diagn Cytopathol; 2018 May; 46(5):429-433. PubMed ID: 29205961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression-A Case Report.
    Sheth H; Kumar P; Shreenivas A; Sambath J; Pragya R; Madre C; Athikari N; Khandare H; Peshattiwar V; Datar R; Limaye S
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34036229
    [No Abstract]   [Full Text] [Related]  

  • 30. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
    Schellhammer P; Sharifi R; Block N; Soloway M; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
    Urology; 1996 Jan; 47(1A Suppl):54-60; discussion 80-4. PubMed ID: 8560679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands.
    Boon E; Bel M; van Boxtel W; van der Graaf WTA; van Es RJJ; Eerenstein SEJ; Baatenburg de Jong RJ; van den Brekel MWM; van der Velden LA; Witjes MJH; Hoeben A; Willems SM; Bloemena E; Smit LA; Oosting SF; ; Jonker MA; Flucke UE; van Herpen CML
    Int J Cancer; 2018 Aug; 143(4):758-766. PubMed ID: 29492965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.
    Sirotnak FM; She Y; Lee F; Chen J; Scher HI
    Clin Cancer Res; 2002 Dec; 8(12):3870-6. PubMed ID: 12473602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aggressive invasive micropapillary salivary duct carcinoma of the parotid gland.
    Yamamoto H; Uryu H; Segawa Y; Tsuneyoshi M
    Pathol Int; 2008 May; 58(5):322-6. PubMed ID: 18429833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary salivary duct carcinoma arising from the Stensen duct.
    Noda K; Hirano T; Okamoto T; Suzuki M
    Ear Nose Throat J; 2016 Sep; 95(9):E15-7. PubMed ID: 27657321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Case of Metastatic Submandibular Salivary Duct Carcinoma that Completely Responded to Pembrolizumab Monotherapy.
    Nakaishi M; Sakamoto K; Sakanushi A; Matsunobu T; Terasaki M; Okubo K
    J Nippon Med Sch; 2023 Sep; 90(4):356-362. PubMed ID: 36273905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eribulin in combination with HER2-targeted antibodies for successful treatment of metastatic salivary duct carcinoma: A report of two cases.
    Fujimi A; Nagamachi Y; Yamauchi N; Nishisato T; Murase K; Takada K; Tsujiwaki M; Sugita S; Hasegawa T; Kato J
    Oral Oncol; 2021 Sep; 120():105287. PubMed ID: 33858766
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.
    Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Sarosdy MF; Vogelzang NJ; Schellenger JJ; Kolvenbag GJ
    Urology; 1997 Sep; 50(3):330-6. PubMed ID: 9301693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry.
    Udager AM; Chiosea SI
    Head Neck Pathol; 2017 Sep; 11(3):288-294. PubMed ID: 28321773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N; Arima K; Sugimura Y
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Capecitabine is effective as palliative chemotherapy in a patient with androgen receptor and HER2 positive metastatic salivary duct carcinoma. A case report.
    Čavka L; Zakotnik B
    J Cancer Res Ther; 2023 Oct; 19(7):2048-2051. PubMed ID: 38376316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.